Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Analysts weigh AbbVie’s lower valuation and pipeline upside against Johnson & Johnson’s broader business mix and steadier margins.

Summary by BizToc
Choosing between AbbVie Inc (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) requires balancing the potential for aggressive pharmaceutical growth against the stability of a diversified medical conglomerate. AbbVie is a focused biopharmaceutical player known for its dominance in immunology, whereas…

2 Articles

The Motley FoolThe Motley Fool
Reposted by
BizTocBizToc
Lean Left

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Saturday, August 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AbbVie icon

AbbVie

Eli Lilly icon

Eli Lilly

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal